William H. Gmeiner, PhD, MBA
Wake Forest Baptist Hospital Cancer Center, Winston-Salem, NC, USA
Research interests: Cancer biology and fluoropyrimidine chemistry with an emphasis on translational science
Dr. Gmeiner received a B.A. from the University of Chicago and Ph.D. from the University of Utah and was an Alberta Heritage Medical Research Fellow.
He is now Professor of Cancer Biology at Wake Forest School of Medicine with appointments in the Department of Physiology and Pharmacology, Molecular Medicine, and the Wake Forest/VirginiaTech biomedical graduate sciences graduate program.
Dr. Gmeiner is an expert in fluoropyrimidine (FP) chemotherapy for treatment of colorectal cancer (CRC) and other malignancies. He is the inventor of fluoropyrimidine polymer technology for cancer treatment with more than 10 issued patents. FP polymers are being studied at the Nanotechnology Characterization Laboratory, part of the U.S. National Cancer Institute (ncl.cancer.gov), and at leading academic medical centers. Dr. Gmeiner has received NIH R01, U01, R21 awards from NIH-NCI and grants from the U.S. Congressionally Directed Medical Research Program, the North Carolina Biotechnology Center and other agencies. Dr. Gmeiner regularly serves on NIH study sections and reviews grants for other leading agencies. He has published approximately 100 peer-reviewed publications. His research focuses on both cancer biology and fluoropyrimidine chemistry and emphasizes translational science.
Editorial Board
Terms of Appointment: August 2020 - July 2022; August 2022 - July 2024